This HTML5 document contains 165 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n11http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
n24http://linked.opendata.cz/resource/drugbank/drug/DB01202/identifier/pharmgkb/
dctermshttp://purl.org/dc/terms/
n25http://linked.opendata.cz/resource/drugbank/drug/DB01202/identifier/kegg-compound/
n17http://linked.opendata.cz/resource/AHFS/
n12http://linked.opendata.cz/resource/drugbank/company/
n30http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n27http://linked.opendata.cz/resource/drugbank/drug/DB01202/identifier/pubchem-compound/
n16http://linked.opendata.cz/resource/drugbank/dosage/
n28http://linked.opendata.cz/resource/drugbank/drug/DB01202/identifier/pubchem-substance/
n26http://linked.opendata.cz/resource/drugbank/drug/DB01202/identifier/kegg-drug/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01202/identifier/drugbank/
n9http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n23http://linked.opendata.cz/resource/drugbank/drug/DB01202/identifier/national-drug-code-directory/
n21http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n22http://linked.opendata.cz/resource/drugbank/drug/DB01202/identifier/chemspider/
n29http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n18http://www.drugs.com/cdi/
n5http://linked.opendata.cz/resource/drugbank/property/
n15http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://linked.opendata.cz/resource/atc/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01202/identifier/wikipedia/
n6http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01202
rdf:type
n3:Drug
n3:description
Levetiracetam is an anticonvulsant medication used to treat epilepsy. Levetiracetam may selectively prevent hypersynchronization of epileptiform burst firing and propagation of seizure activity. Levetiracetam binds to the synaptic vesicle protein SV2A, which is thought to be involved in the regulation of vesicle exocytosis. Although the molecular significance of levetiracetam binding to synaptic vesicle protein SV2A is not understood, levetiracetam and related analogs showed a rank order of affinity for SV2A which correlated with the potency of their antiseizure activity in audiogenic seizure-prone mice.
n3:dosage
n16:271B54FD-363D-11E5-9242-09173F13E4C5 n16:271B54FE-363D-11E5-9242-09173F13E4C5 n16:271B54FF-363D-11E5-9242-09173F13E4C5 n16:271B5500-363D-11E5-9242-09173F13E4C5 n16:271B54F9-363D-11E5-9242-09173F13E4C5 n16:271B54FA-363D-11E5-9242-09173F13E4C5 n16:271B54FB-363D-11E5-9242-09173F13E4C5 n16:271B54FC-363D-11E5-9242-09173F13E4C5 n16:271B5505-363D-11E5-9242-09173F13E4C5 n16:271B5501-363D-11E5-9242-09173F13E4C5 n16:271B5502-363D-11E5-9242-09173F13E4C5 n16:271B5503-363D-11E5-9242-09173F13E4C5 n16:271B5504-363D-11E5-9242-09173F13E4C5 n16:271B54F5-363D-11E5-9242-09173F13E4C5 n16:271B54F6-363D-11E5-9242-09173F13E4C5 n16:271B54F7-363D-11E5-9242-09173F13E4C5 n16:271B54F8-363D-11E5-9242-09173F13E4C5 n16:271B54F1-363D-11E5-9242-09173F13E4C5 n16:271B54F2-363D-11E5-9242-09173F13E4C5 n16:271B54F3-363D-11E5-9242-09173F13E4C5 n16:271B54F4-363D-11E5-9242-09173F13E4C5
n3:group
investigational approved
n3:halfLife
6-8 hours
n3:indication
Used as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.
owl:sameAs
n9:DB01202 n21:DB01202
dcterms:title
Levetiracetam
adms:identifier
n14:Levetiracetam n20:DB01202 n22:390096 n23:0121-4802-05 n24:PA450206 n25:C07841 n26:D00709 n27:441341 n28:46508406
n3:mechanismOfAction
The precise mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown. The antiepileptic activity of levetiracetam was assessed in a number of animal models of epileptic seizures. Levetiracetam did not inhibit single seizures induced by maximal stimulation with electrical current or different chemoconvulsants and showed only minimal activity in submaximal stimulation and in threshold tests. Protection was observed, however, against secondarily generalized activity from focal seizures induced by pilocarpine and kainic acid, two chemoconvulsants that induce seizures that mimic some features of human complex partial seizures with secondary generalization. Levetiracetam also displayed inhibitory properties in the kindling model in rats, another model of human complex partial seizures, both during kindling development and in the fully kindled state. The predictive value of these animal models for specific types of human epilepsy is uncertain. Levetiracetam is thought to stimulate synaptic vesicle protein 2A (SV2A), inhibiting neurotransmitter release.
n3:packager
n12:271B54BA-363D-11E5-9242-09173F13E4C5 n12:271B54BB-363D-11E5-9242-09173F13E4C5 n12:271B54B8-363D-11E5-9242-09173F13E4C5 n12:271B54CF-363D-11E5-9242-09173F13E4C5 n12:271B54B9-363D-11E5-9242-09173F13E4C5 n12:271B54B6-363D-11E5-9242-09173F13E4C5 n12:271B54CD-363D-11E5-9242-09173F13E4C5 n12:271B54B7-363D-11E5-9242-09173F13E4C5 n12:271B54CE-363D-11E5-9242-09173F13E4C5 n12:271B54B4-363D-11E5-9242-09173F13E4C5 n12:271B54CB-363D-11E5-9242-09173F13E4C5 n12:271B54B5-363D-11E5-9242-09173F13E4C5 n12:271B54CC-363D-11E5-9242-09173F13E4C5 n12:271B54B2-363D-11E5-9242-09173F13E4C5 n12:271B54C9-363D-11E5-9242-09173F13E4C5 n12:271B54B3-363D-11E5-9242-09173F13E4C5 n12:271B54CA-363D-11E5-9242-09173F13E4C5 n12:271B54B0-363D-11E5-9242-09173F13E4C5 n12:271B54C7-363D-11E5-9242-09173F13E4C5 n12:271B54B1-363D-11E5-9242-09173F13E4C5 n12:271B54C8-363D-11E5-9242-09173F13E4C5 n12:271B54AE-363D-11E5-9242-09173F13E4C5 n12:271B54C5-363D-11E5-9242-09173F13E4C5 n12:271B54AF-363D-11E5-9242-09173F13E4C5 n12:271B54C6-363D-11E5-9242-09173F13E4C5 n12:271B54AC-363D-11E5-9242-09173F13E4C5 n12:271B54C3-363D-11E5-9242-09173F13E4C5 n12:271B54AD-363D-11E5-9242-09173F13E4C5 n12:271B54C4-363D-11E5-9242-09173F13E4C5 n12:271B54AA-363D-11E5-9242-09173F13E4C5 n12:271B54C1-363D-11E5-9242-09173F13E4C5 n12:271B54AB-363D-11E5-9242-09173F13E4C5 n12:271B54C2-363D-11E5-9242-09173F13E4C5 n12:271B54A8-363D-11E5-9242-09173F13E4C5 n12:271B54BF-363D-11E5-9242-09173F13E4C5 n12:271B54A9-363D-11E5-9242-09173F13E4C5 n12:271B54C0-363D-11E5-9242-09173F13E4C5 n12:271B54A6-363D-11E5-9242-09173F13E4C5 n12:271B54A7-363D-11E5-9242-09173F13E4C5 n12:271B54A4-363D-11E5-9242-09173F13E4C5 n12:271B54A5-363D-11E5-9242-09173F13E4C5 n12:271B54D8-363D-11E5-9242-09173F13E4C5 n12:271B54D9-363D-11E5-9242-09173F13E4C5 n12:271B54D6-363D-11E5-9242-09173F13E4C5 n12:271B54D7-363D-11E5-9242-09173F13E4C5 n12:271B54D4-363D-11E5-9242-09173F13E4C5 n12:271B54D5-363D-11E5-9242-09173F13E4C5 n12:271B54D2-363D-11E5-9242-09173F13E4C5 n12:271B54D3-363D-11E5-9242-09173F13E4C5 n12:271B54D0-363D-11E5-9242-09173F13E4C5 n12:271B54D1-363D-11E5-9242-09173F13E4C5 n12:271B54BD-363D-11E5-9242-09173F13E4C5 n12:271B54BE-363D-11E5-9242-09173F13E4C5 n12:271B54BC-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Sixty-six percent (66%) of the dose is renally excreted unchanged. The metabolites have no known pharmacological activity and are renally excreted. The mechanism of excretion is glomerular filtration with subsequent partial tubular reabsorption.
n3:synonym
Keppra Levetiracetam Levitiracetam Levetiracetamum e Keppra
n3:toxicity
Side effects include aggression, agitation, coma, drowsiness, reduced consciousness, slowed breathing
n6:hasAHFSCode
n17:28-12-92
n3:foodInteraction
Take without regard to meals. Food does not affect bioavailabilty.
n3:proteinBinding
Very low (<10%)
n3:synthesisReference
Tooru Futagawa, Jean-Pierre Canvat, Emile Cavoy, Michel Deleers, Michel Hamende, Vincent Zimmermann, "Process for the preparation of levetiracetam." U.S. Patent US6107492, issued September, 1996.
n29:hasConcept
n30:M0374035
foaf:page
n11:keppra.htm n15:kep1561.shtml n18:levetiracetam.html
n3:IUPAC-Name
n5:271B550A-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B5510-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B550F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B550C-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B550D-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B550E-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B5508-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B5506-363D-11E5-9242-09173F13E4C5 n5:271B5520-363D-11E5-9242-09173F13E4C5 n5:271B5509-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B5507-363D-11E5-9242-09173F13E4C5
n6:hasATCCode
n7:N03AX14
n3:H-Bond-Acceptor-Count
n5:271B5516-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B5517-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B5511-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B5512-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B5514-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B5513-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B5515-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly and almost completely absorbed after oral administration (99%). Peak plasma concentrations occurring in about an hour following oral administration in fasted subjects.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
102767-28-2
n3:category
n3:clearance
* 0.96 mL/min/kg
n3:containedIn
n4:271B54E2-363D-11E5-9242-09173F13E4C5 n4:271B54DF-363D-11E5-9242-09173F13E4C5 n4:271B54E0-363D-11E5-9242-09173F13E4C5 n4:271B54DE-363D-11E5-9242-09173F13E4C5 n4:271B54DD-363D-11E5-9242-09173F13E4C5 n4:271B54E8-363D-11E5-9242-09173F13E4C5 n4:271B54DB-363D-11E5-9242-09173F13E4C5 n4:271B54DC-363D-11E5-9242-09173F13E4C5 n4:271B54DA-363D-11E5-9242-09173F13E4C5 n4:271B54EF-363D-11E5-9242-09173F13E4C5 n4:271B54F0-363D-11E5-9242-09173F13E4C5 n4:271B54ED-363D-11E5-9242-09173F13E4C5 n4:271B54EE-363D-11E5-9242-09173F13E4C5 n4:271B54EB-363D-11E5-9242-09173F13E4C5 n4:271B54EC-363D-11E5-9242-09173F13E4C5 n4:271B54E9-363D-11E5-9242-09173F13E4C5 n4:271B54EA-363D-11E5-9242-09173F13E4C5 n4:271B54E7-363D-11E5-9242-09173F13E4C5 n4:271B54E5-363D-11E5-9242-09173F13E4C5 n4:271B54E6-363D-11E5-9242-09173F13E4C5 n4:271B54E3-363D-11E5-9242-09173F13E4C5 n4:271B54E4-363D-11E5-9242-09173F13E4C5 n4:271B54E1-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B551C-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B551E-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B551F-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B551B-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B551A-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B551D-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B550B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B5518-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B5519-363D-11E5-9242-09173F13E4C5